Leonardo Iaccarino1, Renaud La Joie1, Orit H Lesman-Segev1,2, Eunice Lee3, Lucy Hanna4, Isabel E Allen5, Bruce E Hillner6, Barry A Siegel7, Rachel A Whitmer8,9, Maria C Carrillo10, Constantine Gatsonis4,11, Gil D Rabinovici1,12,13. 1. Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco. 2. Department of Diagnostic Imaging, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel. 3. Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco. 4. Center for Statistical Sciences, Brown University School of Public Health, Providence, Rhode Island. 5. Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco. 6. Department of Medicine, Virginia Commonwealth University, Richmond. 7. Edward Mallinckrodt Institute of Radiology, Washington University School of Medicine in St Louis, St Louis, Missouri. 8. Division of Research, Kaiser Permanente, Oakland, California. 9. Department of Public Health Sciences, University of California, Davis, Davis. 10. Medical and Scientific Relations Division, Alzheimer's Association, Chicago, Illinois. 11. Department of Biostatistics, Brown University School of Public Health, Providence, Rhode Island. 12. Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco. 13. Associate Editor, JAMA Neurology.
Abstract
Importance: Amyloid-β (Aβ) deposition is a feature of Alzheimer disease (AD) and may be promoted by exogenous factors, such as ambient air quality. Objective: To examine the association between the likelihood of amyloid positron emission tomography (PET) scan positivity and ambient air quality in individuals with cognitive impairment. Design, Setting, and Participants: This cross-sectional study used data from the Imaging Dementia-Evidence for Amyloid Scanning Study, which included more than 18 000 US participants with cognitive impairment who received an amyloid PET scan with 1 of 3 Aβ tracers (fluorine 18 [18F]-labeled florbetapir, 18F-labeled florbetaben, or 18F-labeled flutemetamol) between February 16, 2016, and January 10, 2018. A sample of older adults with mild cognitive impairment (MCI) or dementia was selected. Exposures: Air pollution was estimated at the patient residence using predicted fine particulate matter (PM2.5) and ground-level ozone (O3) concentrations from the Environmental Protection Agency Downscaler model. Air quality was estimated at 2002 to 2003 (early, or approximately 14 [range, 13-15] years before amyloid PET scan) and 2015 to 2016 (late, or approximately 1 [range, 0-2] years before amyloid PET scan). Main Outcomes and Measures: Primary outcome measure was the association between air pollution and the likelihood of amyloid PET scan positivity, which was measured as odds ratios (ORs) and marginal effects, adjusting for demographic, lifestyle, and socioeconomic factors and medical comorbidities, including respiratory, cardiovascular, cerebrovascular, psychiatric, and neurological conditions. Results: The data set included 18 178 patients, of which 10 991 (60.5%) had MCI and 7187 (39.5%) had dementia (mean [SD] age, 75.8 [6.3] years; 9333 women [51.3%]). Living in areas with higher estimated biennial PM2.5 concentrations in 2002 to 2003 was associated with a higher likelihood of amyloid PET scan positivity (adjusted OR, 1.10; 95% CI, 1.05-1.15; z score = 3.93; false discovery rate [FDR]-corrected P < .001; per 4-μg/m3 increments). Results were similar for 2015 to 2016 data (OR, 1.15; 95% CI, 1.05-1.26, z score = 3.14; FDR-corrected P = .003). An average marginal effect (AME) of +0.5% (SE = 0.1%; z score, 3.93; 95% CI, 0.3%-0.7%; FDR-corrected P < .001) probability of amyloid PET scan positivity for each 1-μg/m3 increase in PM2.5 was observed for 2002 to 2003, whereas an AME of +0.8% (SE = 0.2%; z score = 3.15; 95% CI, 0.3%-1.2%; FDR-corrected P = .002) probability was observed for 2015 to 2016. Post hoc analyses showed no effect modification by sex (2002-2003: interaction term β = 1.01 [95% CI, 0.99-1.04; z score = 1.13; FDR-corrected P = .56]; 2015-2016: β = 1.02 [95% CI, 0.98-1.07; z score = 0.91; FDR-corrected P = .56]) or clinical stage (2002-2003: interaction term β = 1.01 [95% CI, 0.99-1.03; z score = 0.77; FDR-corrected P = .58]; 2015-2016: β = 1.03; 95% CI, 0.99-1.08; z score = 1.46; FDR-corrected P = .47]). Exposure to higher O3 concentrations was not associated with amyloid PET scan positivity in both time windows. Conclusions and Relevance: This study found that higher PM2.5 concentrations appeared to be associated with brain Aβ plaques. These findings suggest the need to consider airborne toxic pollutants associated with Aβ pathology in public health policy decisions and to inform individual lifetime risk of developing AD and dementia.
Importance: Amyloid-β (Aβ) deposition is a feature of Alzheimer disease (AD) and may be promoted by exogenous factors, such as ambient air quality. Objective: To examine the association between the likelihood of amyloid positron emission tomography (PET) scan positivity and ambient air quality in individuals with cognitive impairment. Design, Setting, and Participants: This cross-sectional study used data from the Imaging Dementia-Evidence for Amyloid Scanning Study, which included more than 18 000 US participants with cognitive impairment who received an amyloid PET scan with 1 of 3 Aβ tracers (fluorine 18 [18F]-labeled florbetapir, 18F-labeled florbetaben, or 18F-labeled flutemetamol) between February 16, 2016, and January 10, 2018. A sample of older adults with mild cognitive impairment (MCI) or dementia was selected. Exposures: Air pollution was estimated at the patient residence using predicted fine particulate matter (PM2.5) and ground-level ozone (O3) concentrations from the Environmental Protection Agency Downscaler model. Air quality was estimated at 2002 to 2003 (early, or approximately 14 [range, 13-15] years before amyloid PET scan) and 2015 to 2016 (late, or approximately 1 [range, 0-2] years before amyloid PET scan). Main Outcomes and Measures: Primary outcome measure was the association between air pollution and the likelihood of amyloid PET scan positivity, which was measured as odds ratios (ORs) and marginal effects, adjusting for demographic, lifestyle, and socioeconomic factors and medical comorbidities, including respiratory, cardiovascular, cerebrovascular, psychiatric, and neurological conditions. Results: The data set included 18 178 patients, of which 10 991 (60.5%) had MCI and 7187 (39.5%) had dementia (mean [SD] age, 75.8 [6.3] years; 9333 women [51.3%]). Living in areas with higher estimated biennial PM2.5 concentrations in 2002 to 2003 was associated with a higher likelihood of amyloid PET scan positivity (adjusted OR, 1.10; 95% CI, 1.05-1.15; z score = 3.93; false discovery rate [FDR]-corrected P < .001; per 4-μg/m3 increments). Results were similar for 2015 to 2016 data (OR, 1.15; 95% CI, 1.05-1.26, z score = 3.14; FDR-corrected P = .003). An average marginal effect (AME) of +0.5% (SE = 0.1%; z score, 3.93; 95% CI, 0.3%-0.7%; FDR-corrected P < .001) probability of amyloid PET scan positivity for each 1-μg/m3 increase in PM2.5 was observed for 2002 to 2003, whereas an AME of +0.8% (SE = 0.2%; z score = 3.15; 95% CI, 0.3%-1.2%; FDR-corrected P = .002) probability was observed for 2015 to 2016. Post hoc analyses showed no effect modification by sex (2002-2003: interaction term β = 1.01 [95% CI, 0.99-1.04; z score = 1.13; FDR-corrected P = .56]; 2015-2016: β = 1.02 [95% CI, 0.98-1.07; z score = 0.91; FDR-corrected P = .56]) or clinical stage (2002-2003: interaction term β = 1.01 [95% CI, 0.99-1.03; z score = 0.77; FDR-corrected P = .58]; 2015-2016: β = 1.03; 95% CI, 0.99-1.08; z score = 1.46; FDR-corrected P = .47]). Exposure to higher O3 concentrations was not associated with amyloid PET scan positivity in both time windows. Conclusions and Relevance: This study found that higher PM2.5 concentrations appeared to be associated with brain Aβ plaques. These findings suggest the need to consider airborne toxic pollutants associated with Aβ pathology in public health policy decisions and to inform individual lifetime risk of developing AD and dementia.
Authors: Osama Sabri; Marwan N Sabbagh; John Seibyl; Henryk Barthel; Hiroyasu Akatsu; Yasuomi Ouchi; Kohei Senda; Shigeo Murayama; Kenji Ishii; Masaki Takao; Thomas G Beach; Christopher C Rowe; James B Leverenz; Bernardino Ghetti; James W Ironside; Ana M Catafau; Andrew W Stephens; Andre Mueller; Norman Koglin; Anja Hoffmann; Katrin Roth; Cornelia Reininger; Walter J Schulz-Schaeffer Journal: Alzheimers Dement Date: 2015-03-28 Impact factor: 21.566
Authors: Craig Curtis; Jose E Gamez; Upinder Singh; Carl H Sadowsky; Teresa Villena; Marwan N Sabbagh; Thomas G Beach; Ranjan Duara; Adam S Fleisher; Kirk A Frey; Zuzana Walker; Arvinder Hunjan; Clive Holmes; Yavir M Escovar; Carla X Vera; Marc E Agronin; Joel Ross; Andrea Bozoki; Mary Akinola; Jiong Shi; Rik Vandenberghe; Milos D Ikonomovic; Paul F Sherwin; Igor D Grachev; Gillian Farrar; Adrian P L Smith; Christopher J Buckley; Richard McLain; Stephen Salloway Journal: JAMA Neurol Date: 2015-03 Impact factor: 18.302
Authors: Michelle L Block; Alison Elder; Richard L Auten; Staci D Bilbo; Honglei Chen; Jiu-Chiuan Chen; Deborah A Cory-Slechta; Daniel Costa; David Diaz-Sanchez; David C Dorman; Diane R Gold; Kimberly Gray; Hueiwang Anna Jeng; Joel D Kaufman; Michael T Kleinman; Annette Kirshner; Cindy Lawler; David S Miller; Srikanth S Nadadur; Beate Ritz; Erin O Semmens; Leonardo H Tonelli; Bellina Veronesi; Robert O Wright; Rosalind J Wright Journal: Neurotoxicology Date: 2012-09-05 Impact factor: 4.294
Authors: Renaud La Joie; Nagehan Ayakta; William W Seeley; Ewa Borys; Adam L Boxer; Charles DeCarli; Vincent Doré; Lea T Grinberg; Eric Huang; Ji-Hye Hwang; Milos D Ikonomovic; Clifford Jack; William J Jagust; Lee-Way Jin; William E Klunk; Julia Kofler; Orit H Lesman-Segev; Samuel N Lockhart; Val J Lowe; Colin L Masters; Chester A Mathis; Catriona L McLean; Bruce L Miller; Daniel Mungas; James P O'Neil; John M Olichney; Joseph E Parisi; Ronald C Petersen; Howard J Rosen; Christopher C Rowe; Salvatore Spina; Prashanthi Vemuri; Victor L Villemagne; Melissa E Murray; Gil D Rabinovici Journal: Alzheimers Dement Date: 2018-10-19 Impact factor: 21.566
Authors: Milos D Ikonomovic; William E Klunk; Eric E Abrahamson; Chester A Mathis; Julie C Price; Nicholas D Tsopelas; Brian J Lopresti; Scott Ziolko; Wenzhu Bi; William R Paljug; Manik L Debnath; Caroline E Hope; Barbara A Isanski; Ronald L Hamilton; Steven T DeKosky Journal: Brain Date: 2008-03-12 Impact factor: 13.501
Authors: Aaron J Cohen; Michael Brauer; Richard Burnett; H Ross Anderson; Joseph Frostad; Kara Estep; Kalpana Balakrishnan; Bert Brunekreef; Lalit Dandona; Rakhi Dandona; Valery Feigin; Greg Freedman; Bryan Hubbell; Amelia Jobling; Haidong Kan; Luke Knibbs; Yang Liu; Randall Martin; Lidia Morawska; C Arden Pope; Hwashin Shin; Kurt Straif; Gavin Shaddick; Matthew Thomas; Rita van Dingenen; Aaron van Donkelaar; Theo Vos; Christopher J L Murray; Mohammad H Forouzanfar Journal: Lancet Date: 2017-04-10 Impact factor: 79.321
Authors: Iain M Carey; H Ross Anderson; Richard W Atkinson; Sean D Beevers; Derek G Cook; David P Strachan; David Dajnak; John Gulliver; Frank J Kelly Journal: BMJ Open Date: 2018-09-11 Impact factor: 2.692
Authors: David Scieszka; Russell Hunter; Jessica Begay; Marsha Bitsui; Yan Lin; Joseph Galewsky; Masako Morishita; Zachary Klaver; James Wagner; Jack R Harkema; Guy Herbert; Selita Lucas; Charlotte McVeigh; Alicia Bolt; Barry Bleske; Christopher G Canal; Ekaterina Mostovenko; Andrew K Ottens; Haiwei Gu; Matthew J Campen; Shahani Noor Journal: Toxicol Sci Date: 2022-02-28 Impact factor: 4.849
Authors: Devin R O'Piela; George R Durisek; Yael-Natalie H Escobar; Amy R Mackos; Loren E Wold Journal: Trends Mol Med Date: 2022-07-12 Impact factor: 15.272
Authors: Diana Younan; Xinhui Wang; Tara Gruenewald; Margaret Gatz; Marc L Serre; William Vizuete; Meredith N Braskie; Nancy F Woods; Ka Kahe; Lorena Garcia; Fred Lurmann; JoAnn E Manson; Helena C Chui; Robert B Wallace; Mark A Espeland; Jiu-Chiuan Chen Journal: J Gerontol A Biol Sci Med Sci Date: 2022-05-05 Impact factor: 6.591
Authors: David A Raichlen; Melissa Furlong; Yann C Klimentidis; M Katherine Sayre; Kimberly L Parra; Pradyumna K Bharadwaj; Rand R Wilcox; Gene E Alexander Journal: Med Sci Sports Exerc Date: 2022-02-08
Authors: Rachel M Shaffer; Ge Li; Sara D Adar; C Dirk Keene; Caitlin S Latimer; Paul K Crane; Eric B Larson; Joel D Kaufman; Marco Carone; Lianne Sheppard Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: Kevin J Sullivan; Xinhui Ran; Fan Wu; Chung-Chou H Chang; Ravi Sharma; Erin Jacobsen; Sarah Berman; Beth E Snitz; Akira Sekikawa; Evelyn O Talbott; Mary Ganguli Journal: J Am Geriatr Soc Date: 2021-04-26 Impact factor: 7.538
Authors: Cheng Chen; Eric A Whitsel; Mark A Espeland; Linda Snetselaar; Kathleen M Hayden; Archana P Lamichhane; Marc L Serre; William Vizuete; Joel D Kaufman; Xinhui Wang; Helena C Chui; Mary E D'Alton; Jiu-Chiuan Chen; Ka Kahe Journal: Alzheimers Dement Date: 2022-02-01 Impact factor: 16.655